Given the well-documented increased in BBB permeability often observed in inflammatory autoimmune CNS diseases, such as myelin oligodendrocyte glycoprotein antibody–associated disease (42) and anti-NMDAR encephalitis (43), we hypothesize that efgartigimod exerts its effects through dual mechanisms. The gene discussed is MOG; the disease is viral encephalitis.